{ "id": "SQ-LIP-000038", "question": "Can screening tools or questionnaires help identify lipedema cases?", "question_pt": "Ferramentas de triagem ou questionários ajudam a identificar casos de lipedema?", "phrasings": [], "phrasings_pt": [], "knowledge_state": "emerging", "tags": [ "Diagnosis", "Screening" ], "keywords": [ "screening", "questionnaire", "case-finding", "lipedema" ], "current_answer": "Based on currently indexed evidence, several screening tools and questionnaires CAN help identify suspected lipedema cases, though all are at an emerging stage and none is a validated standalone diagnostic standard. Symptom-based questionnaires show the most direct screening evidence: a simplified 9-item self-applied tool derived from the validated QuASiL achieved AUC≈0.86–0.91 against expert clinical diagnosis in 109 women (low-grade cross-sectional), and an online version (cutoff ≥12, AUC 0.86) was applied at population scale in Brazil (specificity 0.88 but low sensitivity 0.46). The QuASiL itself was culturally validated with high comprehension and symptom-volume correlation (low grade). Simple clinical decision rules also discriminate: a CART algorithm using just three variables (bruising, body disproportion, spared feet) separated lipedema from lymphedema with reported 100% accuracy in a prospective cohort of 249 patients (moderate grade), and the negative Stemmer sign is repeatedly cited as a key distinguishing clinical feature. Adjunct/objective tools proposed as case-identification aids—DXA leg-fat/total-fat index (AUC 0.90), bioimpedance spectroscopy, quantitative sensory testing (PPT+VDT score, AUC ~0.86–0.91), CT (reported 95% sensitivity/100% specificity), MR lymphangiography, and IL-6 genotyping—each show discriminative signals but rest on small, single-setting, low- or very-low-grade studies. Reviews and guidelines (moderate to very low grade) consistently document substantial underdiagnosis and long diagnostic delay (median ~25 years), supporting the rationale for screening. OUTCOME NOTE: the demonstrated outcome is case IDENTIFICATION/diagnostic discrimination (detecting suspected lipedema), not treatment efficacy or disease modification.", "current_answer_pt": "Com base nas evidências atualmente indexadas, várias ferramentas de triagem e questionários PODEM ajudar a identificar casos suspeitos de lipedema, embora todos estejam em estágio emergente e nenhum seja um padrão diagnóstico isolado validado. Questionários baseados em sintomas apresentam a evidência de triagem mais direta: uma ferramenta autoaplicável simplificada de 9 itens derivada do QuASiL validado alcançou AUC≈0,86–0,91 contra o diagnóstico clínico de especialistas em 109 mulheres (transversal de baixa qualidade), e uma versão online (corte ≥12, AUC 0,86) foi aplicada em escala populacional no Brasil (especificidade 0,88, mas baixa sensibilidade 0,46). O próprio QuASiL foi validado culturalmente com alta compreensão e correlação sintoma-volume (baixa qualidade). Regras clínicas simples também discriminam: um algoritmo CART usando apenas três variáveis (equimoses, desproporção corporal, pés poupados) separou lipedema de linfedema com 100% de acurácia relatada em coorte prospectiva de 249 pacientes (qualidade moderada), e o sinal de Stemmer negativo é repetidamente citado como característica clínica distintiva chave. Ferramentas objetivas/adjuntas propostas—índice de gordura da perna/gordura total por DXA (AUC 0,90), bioimpedância, teste sensorial quantitativo (escore PPT+VDT, AUC ~0,86–0,91), TC (95% sensibilidade/100% especificidade relatada), linfangiografia por RM e genotipagem de IL-6—mostram sinais discriminativos, mas baseiam-se em estudos pequenos, de centro único, de baixa ou muito baixa qualidade. Revisões e diretrizes (qualidade moderada a muito baixa) documentam consistentemente subdiagnóstico substancial e longo atraso diagnóstico (mediana ~25 anos), apoiando a justificativa para triagem. NOTA DE DESFECHO: o desfecho demonstrado é a IDENTIFICAÇÃO de casos/discriminação diagnóstica, não eficácia de tratamento ou modificação da doença.", "bottom_line": "Symptom questionnaires and simple clinical algorithms (using features like bruising, body disproportion, and spared feet) can meaningfully distinguish suspected lipedema from similar conditions, with discrimination scores in the moderate-to-good range across several small studies. No tool has been independently validated against an objective gold standard, sensitivity can be low enough to miss many real cases, and no head-to-head comparison yet establishes which approach works best for broad population screening versus specialist clinical use.", "bottom_line_pt": "Questionários de sintomas e algoritmos clínicos simples (usando características como equimoses, desproporção corporal e pés poupados) podem distinguir casos suspeitos de lipedema de condições semelhantes, com escores de discriminação moderados a bons em vários estudos pequenos. Nenhuma ferramenta foi validada de forma independente contra um padrão-ouro objetivo, a sensibilidade pode ser baixa o suficiente para perder muitos casos reais, e nenhuma comparação direta ainda determina qual abordagem funciona melhor para triagem populacional ampla versus uso clínico especializado.", "major_uncertainty": "Validation is fragmented and mostly low-grade: questionnaires and algorithms are validated against expert clinical diagnosis (no objective gold standard), in single regions/centers, with limited external replication; reported accuracies (including the 100% CART and 95–100% CT figures) lack independent validation and prospective confirmation. Sensitivity of the leading questionnaire is low (0.46), risking missed cases, and no head-to-head comparison establishes which tool is best for population vs clinical screening.", "version": "1.1", "created": "2026-06-02", "updated": "2026-06-02", "compiled_by": { "model": "anthropic/claude-opus-4.8", "label": "Claude Opus 4.8", "date": "2026-06-02" }, "outcomes": [ { "outcome": "Case identification via symptom questionnaire", "outcome_pt": "Identificação de casos via questionário de sintomas", "direction": "improved", "confidence": "low", "disease_modifying": false, "note": "QuASiL-derived tools AUC 0.86-0.91 vs expert dx; but online version sensitivity only 0.46", "note_pt": "Ferramentas derivadas do QuASiL AUC 0,86-0,91 vs dx especialista; mas sensibilidade da versão online só 0,46" }, { "outcome": "Lipedema vs lymphedema discrimination (clinical algorithm)", "outcome_pt": "Discriminação lipedema vs linfedema (algoritmo clínico)", "direction": "improved", "confidence": "moderate", "disease_modifying": false, "note": "3-variable CART (bruising, disproportion, spared feet) 100% accuracy; needs external validation", "note_pt": "CART de 3 variáveis (equimoses, desproporção, pés poupados) 100% acurácia; requer validação externa" }, { "outcome": "Discrimination via imaging/body composition (DXA, CT, BIS, MR)", "outcome_pt": "Discriminação via imagem/composição corporal (DXA, TC, BIS, RM)", "direction": "improved", "confidence": "low", "disease_modifying": false, "note": "DXA leg/total fat AUC 0.90; CT 95% sens/100% spec; all small single-center studies", "note_pt": "DXA gordura perna/total AUC 0,90; TC 95% sens/100% espec; todos estudos pequenos de centro único" }, { "outcome": "Discrimination via quantitative sensory testing (QST)", "outcome_pt": "Discriminação via teste sensorial quantitativo (QST)", "direction": "improved", "confidence": "low", "disease_modifying": false, "note": "PPT+VDT score AUC ~0.86-0.91 in non-obese; preprint, small sample", "note_pt": "Escore PPT+VDT AUC ~0,86-0,91 em não obesas; preprint, amostra pequena" }, { "outcome": "Discrimination via genetic/biomarker panels", "outcome_pt": "Discriminação via painéis genéticos/biomarcadores", "direction": "not_demonstrated", "confidence": "very_low", "disease_modifying": false, "note": "IL-6 rs1800795 association proposed as adjunct; no validated diagnostic biomarker exists", "note_pt": "Associação IL-6 rs1800795 proposta como adjuvante; nenhum biomarcador diagnóstico validado existe" } ], "evidence_direction": { "supporting": 14, "contradicting": 0, "other": 1 }, "knowledge_freshness": { "pct": 60, "sources": 15, "newest": 2026, "oldest": 2012, "small_base": false, "label": "mixed" }, "claims": [ { "id": "SCR-LIP-000188", "role": "supporting", "statement": "A simplified 9-item self-applied screening questionnaire (derived from the validated QuASiL) based on clinical diagnostic criteria (post-pubertal women, bilateral symmetric fat deposit below the hip sparing feet, negative Stemmer and Godet signs, pain on palpation, spontaneous bruising) achieved diagnostic discrimination of AUC=0.912 for an individual 7-question predictive model and AUC=0.8615 for a total-score model against expert clinical diagnosis in 109 women (59 with lipedema, 50 without), with the item 'feeling something wrong in the legs' being most discriminative (OR=4.328)." }, { "id": "SCR-LIP-000009", "role": "supporting", "statement": "The Brazilian Portuguese lipedema symptoms questionnaire (QuASiL) was translated, culturally adapted and validated, showing high comprehension and symptom-intensity scores that correlate with limb volume by segmental bioimpedance." }, { "id": "SCR-LIP-000062", "role": "supporting", "statement": "A narrative review of 2020–2025 evidence concludes that systematic lipedema screening is necessary when studying pain–inflammation relationships in women with obesity, because unrecognized lipedema may cluster pain within peripheral fat phenotypes and bias comparisons between android and gynoid obesity groups." }, { "id": "SCR-LIP-000065", "role": "supporting", "statement": "In a cohort of 1803 Spanish lipedema patients, 60.6% were diagnosed during reproductive years with a mean age of 42.9 years, and the study presents a novel clinical assessment approach including multiple comorbidity markers (e.g., suspected high intestinal permeability in 99%, bilateral trochanteric pain in 97.4%, ligamentous hyperlaxity in 95.8%) that may help physicians better identify and understand the condition." }, { "id": "SCR-LIP-000364", "role": "supporting", "statement": "In a cross-sectional survey of 969 Spanish lipedema patients, diagnoses used the Schingale type I-IV classification (type III 41.7%, type IV 36.8%, type II 17.8%, type I 3.7%) and a modified Wolf/Herbst 13-criteria symptom scale; the authors validated a threshold of ≥6 of 13 symptoms (Mann-Whitney p=0.666 showing no distributional difference between diagnosed and undiagnosed groups), and diagnosis often required multiple consultations (51.2% needed ≥3 specialists)." }, { "id": "SCR-LIP-000068", "role": "supporting", "statement": "Dutch lipedema guidelines conclude that lipedema is frequently misdiagnosed or wrongly classified as an aesthetic problem, and recommend a minimum data set of repeated clinical measurements (waist circumference, limb circumferences, BMI, and psychosocial distress scoring) to ensure early detection." }, { "id": "SCR-LIP-000275", "role": "supporting", "statement": "Using a previously validated online screening questionnaire (cutoff ≥12 points, AUC 0.8615, specificity 0.88, sensitivity 0.46, PPV 0.767), a population-representative study estimated lipedema prevalence at 12.3% among Brazilian women aged 18-69, corresponding to roughly 8.8 million women with suggestive symptoms." }, { "id": "SCR-LIP-000358", "role": "supporting", "statement": "The authors propose a clinical-ultrasonographic diagnostic algorithm for abdominal lipedema using maximum criteria (symmetric abdominal fat deposition + ultrasonographic evidence + inelastic skin), major criteria (pain on palpation + non-response to diet/exercise), and minor criteria (easy bruising + heaviness), correlating abdominal involvement with lipedema stage (31% in stage II, 70% in stage III)." }, { "id": "SCR-LIP-000277", "role": "supporting", "statement": "In non-obese lipedema patients, standardized QST (DFNS protocol) revealed selective alterations in only 2 of 13 parameters at the affected lateral thigh—elevated pressure pain (PPT, AUC 0.9075) and reduced vibration detection (VDT, AUC 0.8638)—and a combined PPT+VDT z-score score was proposed as a rapid diagnostic test for lipedema." }, { "id": "SCR-LIP-000199", "role": "supporting", "statement": "In a DXA body composition study, the leg fat mass/total fat mass index distinguished lipedema patients from healthy controls with AUC=0.90 (sensitivity 0.95, specificity 0.73 at cutoff 0.383) across all BMI strata, with elevated leg fat proportion (0.451 vs 0.354) and inverted trunk/legs ratio (0.960 vs 1.502), while appendicular lean mass and total bone density did not differ." }, { "id": "SCR-LIP-000279", "role": "context", "statement": "This editorial commenting on Crescenzi et al. (2023) emphasizes the lack of reliable lipedema biomarkers and highlights noncontrast 3T MR lymphangiography—which reveals subcutaneous adipose tissue edema and increased lymphatic load—as a promising imaging biomarker that could aid differential diagnosis between lipedema and obesity, while noting small sample sizes limit current evidence." }, { "id": "SCR-LIP-000285", "role": "supporting", "statement": "A systematic review reported that lipedema is poorly recognized clinically—only 46.2% of 251 Vascular Society of Great Britain and Ireland consultants recognized it (Tiwari 2006)—and that it was absent from MeSH/EMBASE and ICD-WHO as of 2012, while non-contrast CT showed 95% sensitivity and 100% specificity and the spared foot dorsum (negative Stemmer sign) helps distinguish lipedema from lymphedema." }, { "id": "SCR-LIP-000191", "role": "supporting", "statement": "Bioimpedance spectroscopy of regional tissue fluid distinguished lipedema from Dercum's disease (lower leg/arm R0 ratio in lipedema, p<0.001) and detected stage 1 lipedema versus matched controls (leg/arm ratio R0 p=0.01, R1 p=0.007), with leg extracellular water increasing across lipedema stages (p=0.03), proposing BIS as an objective adjunct biomarker for diagnosis and staging." }, { "id": "SCR-LIP-000287", "role": "supporting", "statement": "In a case-control study, carriers of the IL-6 rs1800795 G allele had a 5.92-fold higher risk of lipedema (OR=5.92, 95%CI 1.983–17.711, p<0.001), and DXA-derived body composition indices (reduced WHR 0.73 vs 0.79, higher lower-limb FM% 48.90% vs 42.55%) combined with genetic analysis were proposed as tools for differential diagnosis between lipedema, normal-weight obesity, and obesity." }, { "id": "SCR-LIP-000288", "role": "supporting", "statement": "In a prospective cohort of 138 lipedema and 111 lymphedema patients, a CART algorithm using only three clinical variables (bruising, body disproportion, and non-swollen/spared feet) classified lipedema versus lymphedema with 100% accuracy, and the median time from symptom onset to diagnosis was markedly longer in lipedema (25.5 years vs 12.1 years for lymphedema, p<0.0001)." } ], "references": [ "DOI:10.1590/1677-5449.200114", "DOI:10.1590/1677-5449.200049", "DOI:10.36557/2674-8169.2026v8n2p869-884", "DOI:10.3390/biomedicines13123049", "DOI:10.3390/ijerph20176647", "DOI:10.1177/0268355516639421", "DOI:10.1590/1677-5449.202101981", "DOI:10.1007/s00266-025-05192-1", "DOI:10.1101/2023.04.25.23289086", "DOI:10.1159/000527138", "DOI:10.1002/jmri.28400", "DOI:10.1111/j.1758-8111.2012.00045.x", "DOI:10.1089/lrb.2019.0011", "DOI:10.26355/eurrev_202003_20690", "DOI:10.23736/s0392-9590.25.05207-1" ], "cite": "Scientific Claim Registry. Can screening tools or questionnaires help identify lipedema cases?. SQ-LIP-000038 v1.1; 2026-06-02. https://scientificclaims.org/q/SQ-LIP-000038/v1.1.html", "versions": [ { "version": "1.1", "date": "2026-06-02", "url": "https://scientificclaims.org/q/SQ-LIP-000038/v1.1.html" }, { "version": "1.0", "date": "2026-06-02", "url": "https://scientificclaims.org/q/SQ-LIP-000038/v1.0.html" } ], "url": "https://scientificclaims.org/q/SQ-LIP-000038.html", "url_pt": "https://scientificclaims.org/pt/q/SQ-LIP-000038.html", "version_url": "https://scientificclaims.org/q/SQ-LIP-000038/v1.1.html", "license": "CC-BY-4.0", "disclaimer": "Evidence-bounded summary; not medical advice." }